BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

572 related articles for article (PubMed ID: 7962341)

  • 1. Arginine and growth hormone-releasing hormone restore the blunted growth hormone-releasing activity of hexarelin in elderly subjects.
    Arvat E; Gianotti L; Grottoli S; Imbimbo BP; Lenaerts V; Deghenghi R; Camanni F; Ghigo E
    J Clin Endocrinol Metab; 1994 Nov; 79(5):1440-3. PubMed ID: 7962341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth hormone (GH) responsiveness to combined administration of arginine and GH-releasing hormone does not vary with age in man.
    Ghigo E; Goffi S; Nicolosi M; Arvat E; Valente F; Mazza E; Ghigo MC; Camanni F
    J Clin Endocrinol Metab; 1990 Dec; 71(6):1481-5. PubMed ID: 2229304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arginine enhances the growth hormone-releasing activity of a synthetic hexapeptide (GHRP-6) in elderly but not in young subjects after oral administration.
    Ghigo E; Arvat E; Rizzi G; Bellone J; Nicolosi M; Boffano GM; Mucci M; Boghen MF; Camanni F
    J Endocrinol Invest; 1994 Mar; 17(3):157-62. PubMed ID: 8051337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man.
    Ghigo E; Arvat E; Gianotti L; Imbimbo BP; Lenaerts V; Deghenghi R; Camanni F
    J Clin Endocrinol Metab; 1994 Mar; 78(3):693-8. PubMed ID: 8126144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction of the somatotrope responsiveness to GHRH and Hexarelin but not to arginine plus GHRH in hyperprolactinemic patients.
    Grottoli S; Razzore P; Arvat E; Oleandri SE; Rossetto R; Ciccarelli E; Camanni F; Ghigo E
    J Endocrinol Invest; 1997 Nov; 20(10):597-602. PubMed ID: 9438917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age-related variations in the neuroendocrine control, more than impaired receptor sensitivity, cause the reduction in the GH-releasing activity of GHRPs in human aging.
    Arvat E; Ceda GP; Di Vito L; Ramunni J; Gianotti L; Broglio F; Deghenghi R; Ghigo E
    Pituitary; 1998 Apr; 1(1):51-8. PubMed ID: 11081183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of growth hormone-releasing activity of hexarelin in man.
    Arvat E; Gianotti L; Di Vito L; Imbimbo BP; Lenaerts V; Deghenghi R; Camanni F; Ghigo E
    Neuroendocrinology; 1995 Jan; 61(1):51-6. PubMed ID: 7731498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hexarelin, a synthetic GH-releasing peptide, is a powerful stimulus of GH secretion in pubertal children and in adults but not in prepubertal children and in elderly subjects.
    Bellone J; Bartolotta E; Sgattoni C; Aimaretti G; Arvat E; Bellone S; Deghenghi R; Ghigo E
    J Endocrinol Invest; 1998 Sep; 21(8):494-500. PubMed ID: 9801989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of 15-day treatment with growth-hormone-releasing hormone alone or combined with different doses of arginine on the reduced somatotrope responsiveness to the neurohormone in normal aging.
    Ghigo E; Ceda GP; Valcavi R; Goffi S; Zini M; Mucci M; Valenti G; Muller EE; Camanni F
    Eur J Endocrinol; 1995 Jan; 132(1):32-6. PubMed ID: 7850007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of histaminergic antagonists on the GH-releasing activity of GHRH or hexarelin, a synthetic hexapeptide, in man.
    Arvat E; Maccagno B; Ramunni J; Gianotti L; Di Vito L; Deghenghi R; Camanni F; Ghigo E
    J Endocrinol Invest; 1997 Mar; 20(3):122-7. PubMed ID: 9186817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low doses of either intravenously or orally administered arginine are able to enhance growth hormone response to growth hormone releasing hormone in elderly subjects.
    Ghigo E; Ceda GP; Valcavi R; Goffi S; Zini M; Mucci M; Valenti G; Cocchi D; Müller EE; Camanni F
    J Endocrinol Invest; 1994 Feb; 17(2):113-7. PubMed ID: 8006330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic modulation of the growth hormone-releasing activity of hexarelin in man.
    Maccario M; Arvat E; Procopio M; Gianotti L; Grottoli S; Imbimbo BP; Lenaerts V; Deghenghi R; Camanni F; Ghigo E
    Metabolism; 1995 Jan; 44(1):134-8. PubMed ID: 7854159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence against depletion of the growth hormone (GH)-releasable pool in human primary hypothyroidism: studies with GH-releasing hormone, pyridostigmine, and arginine.
    Valcavi R; Valente F; Dieguez C; Zini M; Procopio M; Portioli I; Ghigo E
    J Clin Endocrinol Metab; 1993 Sep; 77(3):616-20. PubMed ID: 8103770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction of the growth hormone releasing peptide hexarelin with somatostatin.
    Massoud AF; Hindmarsh PC; Brook CG
    Clin Endocrinol (Oxf); 1997 Nov; 47(5):537-47. PubMed ID: 9425393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth hormone response to hexarelin, growth hormone-releasing hormone plus pyridostigmine and arginine plus estrogen in prepubertal and early pubertal short children.
    Guzzaloni G; Grugni G; Morabito F
    Minerva Endocrinol; 1998 Dec; 23(4):99-104. PubMed ID: 10361807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The GH-releasing effect of Hexarelin, a synthetic hexapeptide, in newborns is lower than in young adults.
    Bartolotta E; Bellone J; Aimaretti G; Arvat E; Benso L; Deghenghi R; Camanni F; Ghigo E
    J Pediatr Endocrinol Metab; 1997; 10(5):491-7. PubMed ID: 9401905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone.
    Arvat E; Maccario M; Di Vito L; Broglio F; Benso A; Gottero C; Papotti M; Muccioli G; Dieguez C; Casanueva FF; Deghenghi R; Camanni F; Ghigo E
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1169-74. PubMed ID: 11238504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of recombinant human insulin-like growth factor I administration on growth hormone (GH) secretion, both spontaneous and stimulated by GH-releasing hormone or hexarelin, a peptidyl GH secretagogue, in humans.
    Ghigo E; Gianotti L; Arvat E; Ramunni J; Valetto MR; Broglio F; Rolla M; Cavagnini F; Müller EE
    J Clin Endocrinol Metab; 1999 Jan; 84(1):285-90. PubMed ID: 9920097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low hexarelin dose and pyridostigmine have additive effect and potentiate to the same extent the GHRH-induced GH response in man.
    Arvat E; Di Vito L; Ramunni J; Gianotti L; Giordano R; Deghenghi R; Camanni F; Ghigo E
    Clin Endocrinol (Oxf); 1997 Oct; 47(4):495-500. PubMed ID: 9404449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contribution of growth hormone-releasing hormone and somatostatin to decreased growth hormone secretion in elderly men.
    Soule SG; Macfarlane P; Levitt NS; Millar RP
    S Afr Med J; 2001 Mar; 91(3):254-60. PubMed ID: 11291426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.